证券代码：002644 证券简称：佛慈制药 公告编号：2025-020 兰州佛慈制药股份有限公司 第八届董事会第八次会议决议公告 兰州佛慈制药股份有限公司（以下简称"公司"）第八届董事会第八次会议于 2025 年 8 月 26 日 9:30 在公司五楼会议室以现场与通讯表决相结合的方式召开， 会议由董事长单小东先生主持。会议通知于 2025 年 8 月 22 日以书面、电子邮件、 电话等方式送达。会议应出席董事 6 人，实际出席董事 6 人。公司高级管理人员 列席会议。本次会议的召开符合《公司法》《公司章程》《董事会议事规则》及 有关法律法规的规定。 二、董事会会议审议情况 与会董事经过审议，通过以下议案： 1.审议通过了《2025 年半年度报告及报告摘要》 《2025 年半年度报告及报告摘要》详见 2025 年 8 月 27 日《证券时报》《证 券日报》及巨潮资讯网（www.cninfo.com.cn）。 本议案已经董事会审计委员会审议通过。 表决结果：6 票同意，0 票反对，0 票弃权。 2.审议通过了《关于经理层经营业绩责任书的议案》 同意公司经理层《任期经营业绩责任书（2025 年—2027 年）》《 ...

格隆汇8月26日丨佛慈制药(002644.SZ)公布2025年半年度报告，上半年公司实现营业收入4.29亿元，同 比下降13.93%；归属于上市公司股东的净利润3010.46万元，同比下降16.60%；归属于上市公司股东的 扣除非经常性损益的净利润2085.09万元，同比下降24.91%；基本每股收益0.0590元。 ...

兰州佛慈制药股份有限公司 2025 年半年度报告全文 兰州佛慈制药股份有限公司 2025 年半年度报告 2025 年 8 月 1 兰州佛慈制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人单小东、主管会计工作负责人岳金风及会计机构负责人(会计 主管人员)王凌声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告"第三节 管理层讨论与分析"中分析了公司未来发展可能 面临的风险因素和应对措施，敬请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 兰州佛慈制药股份有限公司 2025 年半年度报告全文 备查文件目录 一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表； 二、报告期内在中国证监会指定信息披露媒体上披露过的所有公司文件的正本及公告的原稿。 4 兰州佛慈制药股份有限公司 2025 年半年度报告全文 2 | | 1 œ ...

Core Insights - The company emphasizes its commitment to research and innovation in the pharmaceutical sector, particularly in the development of innovative drugs [2] Group 1: Research and Development - The company is increasing its investment in research and development, collaborating with institutions such as Lanzhou University and the Chinese Academy of Traditional Chinese Medicine [2] - It is working on the development of three new drugs based on ancient classic formulas, classified as Category 3.1 new drugs, to promote the inheritance and innovation of traditional Chinese medicine [2] Group 2: Product Development - The company is conducting secondary research and development on existing unique and specialty products, including Shenrong Guoben Shaowan, Compound Huangqi Jianpi Oral Liquid, Shugan Xiaojie Wan, and Xiaozhi Wan [2] - The focus of this research includes exploring the efficacy of active ingredients, identifying new functions, and validating clinical data to accelerate the cultivation of major products and enhance market competitiveness [2]

（文章来源：证券日报） 证券日报网讯佛慈制药8月4日在互动平台回答投资者提问时表示，公司目前不存在应披露未披露的信 息。公司将严格按照相关法律法规的要求履行信息披露义务，具体情况请以公司公告信息为准。 ...

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

陇神戎发涨超10%，奇正藏药此前涨停，粤万年青、新天药业、盘龙药业、佛慈制药等跟涨。 (本文来自第一财经) ...

每经AI快讯，8月4日，中药股探底回升，陇神戎发一度涨超10%，奇正藏药此前涨停，粤万年青、新天 药业、盘龙药业、佛慈制药等跟涨。 （文章来源：每日经济新闻） ...

Core Insights - As of August 1, 2025, Foci Pharmaceutical (002644) closed at 10.43 yuan, down 1.42% with a turnover rate of 12.58% and a trading volume of 642,200 lots, amounting to 678 million yuan [1] - The latest quarterly report shows total revenue of 216 million yuan, a year-on-year decrease of 21.22%, while net profit attributable to shareholders was 19.38 million yuan, an increase of 5.41% [1] - The company has a current ratio of 3.630, a quick ratio of 2.665, and a debt-to-asset ratio of 24.19% [1] Financial Performance - Total revenue for Q1 2025 was 216 million yuan, down 21.22% year-on-year [1] - Net profit attributable to shareholders was 19.38 million yuan, up 5.41% year-on-year [1] - Non-recurring net profit was 14.35 million yuan, a slight decrease of 0.48% year-on-year [1] Capital Flow - Main capital outflow today was 29.50 million yuan, accounting for 4.35% of the total trading volume [1] - Large orders saw a net outflow of 12.98 million yuan, representing 1.92% of the trading volume [1] - Small orders experienced a net inflow of 12.20 million yuan, accounting for 1.80% of the trading volume [1] Company Overview - Foci Pharmaceutical Co., Ltd. was established in 2000 and is located in Lanzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 510.657 million yuan and a paid-in capital of 510.65 million yuan [2] - The legal representative of the company is Shan Xiaodong [2] Investment and Intellectual Property - The company has invested in 14 enterprises and participated in 2,083 bidding projects [2] - Foci Pharmaceutical holds 74 trademark registrations and 102 patents [2] - The company possesses 1,180 administrative licenses [2]

（原标题：佛慈制药7月31日龙虎榜数据） 佛慈制药今日跌停，全天换手率15.63%，成交额8.91亿元，振幅12.00%。龙虎榜数据显示，营业部席位合计净卖出8763.98万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-8.61%上榜，营业部席位合计净卖出8763.98万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交1.95亿元，其中，买入成交额为5373.75万元，卖出成交额为1.41亿元，合计净卖出 8763.98万元。 具体来看，今日上榜营业部中，第一大买入营业部为东方财富证券股份有限公司拉萨东环路第二证券营业部，买入金额为1416.04万元，第一大卖 出营业部为国信证券股份有限公司北京分公司，卖出金额为4993.58万元。 资金流向方面，今日该股主力资金净流出6185.55万元，其中，特大单净流出2192.06万元，大单资金净流出3993.49万元。近5日主力资金净流入 5877.74万元。（数据宝） 佛慈制药7月31日交易公开信息 ★ 跟踪：中证数字经济主题指数 近五日涨跌: -0.12% 市盈率：62.25倍 资金流向：最新份额为9.5亿份，减少了800.0万份，主力资金净 ...